Grifols GRFS · NASDAQ
$7.64 +1.33% (+$0.10)
Summary
59 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 23% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- Repaying its net debt would take 4.6 years of operating profit.
- It missed profit estimates 5 times in the last 8 quarters.
- It earns only 5.5 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.6 EUR for 1 EUR of yearly profit. Over the last five years it was 55.6 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 6.2% a year over 5 years. Over the last 3 years it grew by 6.0% a year. For the next fiscal year analysts expect revenue to grow by 7.5%. Earnings per share grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 63 EUR
- Research and development 5.5 EUR
- Sales and administration 15 EUR
- Taxes and other 11 EUR
- Net profit 6.1 EUR
Net profit, industry median (Drug Manufacturers - General) 14 EUR
Out of every 100 EUR of revenue, 6.1 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 11.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.25%
- Paid out of profit
- 16%
You receive $0.09 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 2
- Sell 2
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Haemoderivatives 86%
- Transfusional medicine 8.3%
- Other Product 3.2%
- Bio supplies 2.0%
- Other diagnostic 0.2%
By region
- USA and Canada. 60%
- Rest of the world 23%
- Rest of European Union 17%
Haemoderivatives brings in 86% of revenue. Other Product grew fastest, by 57% a year.
Segments in detail